-
Posted by
Two Blokes Jul 7 -
Filed in
Stock
-
3 views
LivaNova offers strong medtech upside with market-leading positions in cardiac surgery and neuromodulation, but lacks a dividend yield. Recent results show double-digit organic growth, margin expansion, and a positive sales trajectory, especially in Cardiopulmonary. Valuation is attractive: at a discounted 17x P/E, I see 20%+ annual upside and limited downside risk at current prices.
